Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinibprotects hematopoietic progenitors from chemotherapy

Samuel Taylor, Wallace Langdon

Research output: Contribution to journalEditorialpeer-review

Abstract

Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent workoutlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming doseof the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequentialquizartinib primed injections offluorouracil (5-FU), we demonstrated a novel and effective strategy toeliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).
Original languageEnglish
Article numbere1378156
JournalMolecular & Cellular Oncology
Volume4
Issue number6
DOIs
Publication statusPublished - 2 Nov 2017

Fingerprint

Dive into the research topics of 'Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinibprotects hematopoietic progenitors from chemotherapy'. Together they form a unique fingerprint.

Cite this